Urgent warning about EVE headache tablets with apronal by Therapeutic Goods Administration

The Australian Medical and Therapeutic Regulator has issued an urgent warning about a common headache medication that contains a dangerous sedative that poses a significant health risk.

The Therapeutic Goods Administration (TGA) has issued a safety alert for EVE brand tablets containing allylisopropyl acetylurea, also known as apron.

The hypnotic sedative has been found in a range of imported products, including EVE Quick for Headache, EVE Quick for Headache DX EVE, EVE A, and EVE A EX.

The products are prohibited for sale, supply and use in Australia.

“We warn consumers against the use of EVE branded products containing allyl isopropyl acetylurea as they pose a significant health risk and should not be sold, supplied or used in Australia,” the TGA warning reads.

“Apronal is a hypnotic sedative that has been withdrawn from the market in Australia due to dangerous side effects and is banned in most countries around the world.”

“If you or someone you care for is using any of these products, discontinue immediately and take any remaining tablets to your local pharmacy for safe disposal.”

Apronal is also called Apronalide, ACE and (2-isopropyl-4-pentenoyl)urea.

Synthesized in 1926 by Hoffmann-La Roche, apron is no longer used except in Japan.

Consumers and businesses are reminded that it is illegal to import, advertise or supply unregistered therapeutic goods into Australia, including EVE or any brand of apron products.

The illegal importation and supply of these products can lead to heavy fines or legal action.

Consumers are also warned to exercise extreme caution when purchasing drugs from unknown overseas websites as they may contain undisclosed and potentially harmful ingredients.

They may also not meet the same quality, safety and efficacy standards as those approved in Australia.